U.S. Pharma is largely immune from ‘MAHA’ impact: Wolfe

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement “Make America Healthy Again,” championed by Robert F. Kennedy Jr., President-elect Donald Trump’s nominee for HHS Secretary.

In a research